Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.

Abstract Purpose In order to evaluate the feasibility of dose-dense docetaxel followed by dose-dense AC (doxorubicin/cyclophosphamide) as adjuvant chemotherapy for operable breast cancer, we conducted a phase II study. Patients and Methods In cohort 1, 28 patients received docetaxel 100 mg/m 2 followed by doxorubicin 60 mg/m 2 with cyclophosphamide 600 mg/m 2 , each every 2 weeks for 4 weeks (total of 8 cycles). Enrollment was discontinued because of stopping criteria based on significant toxicity (grade 4 hematologic toxicity or grade ≥ 3 nonhematologic toxicity). In cohort 2, the docetaxel dose was reduced to 75 mg/m 2 ; enrollment was discontinued after 18 patients. Results Significant toxicity occurred in 79% and 72% of patients in cohorts 1 and 2, respectively, resulting in treatment delays in 50% and 17% of patients, respectively. The most common grade 4 hematologic toxicity was neutropenia, which occurred in 7% and 42% of cohort 1 patients during docetaxel and AC, respectively, and in none and 19% of cohort 2 patients, respectively. The most common grade ≥ 3 nonhematologic toxicity was palmar-plantar erythrodysesthesia, which occurred in 25% and none of cohort 1 patients during docetaxel and AC, respectively. With docetaxel 75 mg/m 2 and patient education encouraging routine use of topical strategies, grade 3 palmar-plantar erythrodysesthesia occurred in only 11% of cohort 2 patients. Grade 2 nail changes were also debilitating and occurred in 33% of cohort 1 patients during AC. Conclusion These phase II findings suggest that dose-dense docetaxel 100 mg/m 2 followed by AC is not feasible and, until more studies are conducted, should be restricted to clinical studies.